Daawada biocon ee loogu talagalay COVID 19 ALZUMAb® (Itolizumab)

Dawooyinka Biocon ee COVID-19: ALZUMAb® (Itolizumab)

Faafida COVID-19 ayaa saameyn weyn ku yeelatay adduunka, taasoo keentay khasaare nafeed iyo dhaqaale xumo baahsan. Baahida loo qabo dawooyin iyo tallaalo wax ku ool ah si loola dagaallamo fayraska waa muhiim. Biocon, oo ah shirkad hormuud ka ah biopharmaceutical, ayaa soo saartay dawo la yiraahdo ALZUMAb® (Itolizumab) si loogu daweeyo COVID-19.

Waa maxay ALZUMAb® (Itolizumab)?

ALZUMAb® (Itolizumab) waa dawada ka hortagta unugyada monoclonal ee bini'aadminimo oo laga isticmaalay Hindiya dhowr sano si loogu daweeyo psoriasis, cudur maqaarka ah oo raaga. Bishii Juun 2020, Kormeeraha Guud ee Dawooyinka ee Hindiya (DCGI) ayaa oggolaaday isticmaalka ALZUMAb® (Itolizumab) ee loogu isticmaalo xaaladaha degdegga ah ee bukaannada COVID-19 ee qaba xanuunka neef-mareenka ee dhexdhexaadka ah ama daran (ARDS).

Sidee buu ALZUMab® (Itolizumab) u shaqeeyaa?

ALZUMAB® (Itolizumab) waxay u shaqeysaa iyadoo lagu xirayo borotiin gaar ah oo la yiraahdo CD6 kaas oo lagu muujiyo dusha sare ee unugyada T, oo ah nooca unugyada difaaca. Marka lagu xidho CD6, ALZUMAb® (Itolizumab) waxay ka hortagtaa firfircoonida iyo badinta unugyada T, taas oo u horseedi karta jawaab celin difaac oo xad dhaaf ah ama duufaanka cytokine ee bukaannada COVID-19. Duufaanta cytokine waxay sababi kartaa dhaawac daran oo sambabada ah iyo cillad xagga neefsashada ah, taasoo u horseedaysa heer dhimasho sare ah bukaannada COVID-19.

Tijaabooyinka caafimaad ee ALZUMAb® (Itolizumab)

Biocon waxay samaysay tijaabada caafimaad ee Wajiga II ee ALZUMAb® (Itolizumab) ee bukaannada COVID-19 ee leh ARDS dhexdhexaad ah ama daran. Tijaabadu waxa ay diiwaangelisay 30 bukaan, kuwaas oo 20 ka mid ah ay heleen ALZUMAb® (Itolizumab) iyo 10 ay heleen heerka daryeelka. Natiijooyinka tijaabada ayaa muujisay in ALZUMAb® (Itolizumab) ay si weyn hoos ugu dhigtay heerka dhimashada ee bukaannada COVID-19 ee leh ARDS dhexdhexaad ah ama daran. Heerka dhimashada ee kooxda ALZUMAb® (Itolizumab) waxay ahayd 15%, marka la barbar dhigo 40% heerka kooxda daryeelka.

Intaa waxaa dheer, ALZUMAb® (Itolizumab) waxay hagaajisay ogsijiinta waxayna yaraysay caabuqa bukaannada COVID-19. Daawadu si wanaagsan ayaa loo dulqaatay iyada oo aan la soo sheegin dhacdooyin xun oo muhiim ah.

Tijaabada bukaan-socodka ee Wajiga II ee ALZUMAb® (Itolizumab) waxaa ku xigay tijaabada bukaan-socodka ee Wajiga III, kaas oo diiwaangeliyay 30 bukaan oo qaba COVID-19 dhexdhexaad iyo mid daran. Natiijooyinka tijaabada Wajiga III waa la sugayaa.

Ugu Dambeyn

ALZUMAb® (Itolizumab) waxay muujisay natiijooyin rajo leh tijaabooyin caafimaad oo loogu talagalay daawaynta bukaannada COVID-19 ee leh ARDS dhexdhexaad ah ama daran. Daawadu waxay u shaqaysaa iyada oo ku xidhan CD6 iyo ka hortagga firfircoonida iyo badinta unugyada T, taas oo u keeni karta duufaan cytokine bukaannada COVID-19. ALZUMAb® (Itolizumab) ayaa loo oggolaaday isticmaalka degdegga ah ee Hindiya, iyo ammaankeeda iyo waxtarkeeda ayaa lagu daraaseeyaa tijaabooyinka caafimaad ee socda. Haddii natiijooyinka tijaabada Wajiga III ay yihiin kuwa togan, ALZUMAb® (Itolizumab) waxay u noqon kartaa ikhtiyaar daawaynta qiimo leh bukaannada COVID-19.